https://www.selleckchem.com/pr....oducts/pmsf-phenylme
Subcutaneous (SC) formulations of therapeutics with recombinant human hyaluronidase PH20 (rHuPH2 are currently approved across various disease indications. The rHuPH20-mediated enzymatic degradation of SC hyaluronan (HA) facilitates bulk fluid flow and dispersion of co-administered therapeutics. However, current methods of quantifying dispersion in the SC space are limited. Here, a novel method is outlined to quantify and follow rapid SC volumetric dispersion of a representative therapeutic fluid in the pres
Aimer
Commentaire
Partagez
